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ABSTRACT
Analysis of data on asthma deaths from the vital statistics throughout Japan and deaths from asthma attacks in
six prefectures of Tohoku district provided information on recent trends and insight into possible future issues
about asthma deaths in Japan. The vital statistics throughout Japan show a favorable downward trend in the
number of asthma deaths in Japan since 1997. In particular, the asthma mortality rate among persons aged 5
to 34 years was less than 0.3 per 100,000 in 2001. In addition, the number of deaths from asthma attacks de-
creased more rapidly in the Tohoku district and the rate of reduction was correlated with an increase in the
sales of inhaled corticosteroids and anti-leukotrienes but not in the sales of inhaled short-acting β-agonists.
Moreover, in the 5 year period from 1997 through 2001 it was clear that the number of asthma deaths in per-
sons 75 years and older and those 60 years and older accounted for 61―66% and 86―88%, respectively, of the
deaths in persons of all ages. Therefore, the most important future issue about asthma deaths in Japan should
be to focus efforts on decreasing the number of asthma deaths in older persons．
KEY WORDS
anti-leukotrienes, asthma death, deaths from asthma attacks, inhaled corticosteroids, inhaled short-acting β-
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INTRODUCTION
Japanese vital statistics supplied by the Department
of the Ministry of Health, Labour and Welfare of Ja-
pan show a gradual reduction in the number of
asthma deaths since the 1950s. During the same peri-
ods, however, the number of deaths in the 5- to 34-
year-old-age group showed two ‘epidemics’ that oc-
curred at the same time as similar epidemics in some
other countries. It has been suggested that these epi-
demics occurred in parallel with the increase in the
total sales of two different β-adrenergic agonists . 1,2
There were increased sales for isoprenaline during
the first epidemic and for fenoterol during the second
epidemic. In addition, the mortality rate in the 5- to
34-year-old group was disproportionately higher in Ja-
pan than in the other countries with similar epidem-
ics.3 While the mortality rate decreased significantly
during the late 1990s, the case-fatality rate remained
greater in Japan than in other countries.4
This report summarizes an analysis of data on the
annual number of asthma deaths obtained from Japa-
nese vital statistics and the annual number of deaths
due to asthma attacks obtained from a questionnaire
survey in the Tohoku district from 1992 to 2001. 5
This report revealed the following data ; 1) a recent
change in asthma deaths in the 5- to 34-year-old-age
group of Japan , 2 ) an association with the annual
number of deaths from asthma attacks over the pe-
riod 1992―2001 and the sales of anti-asthmatic agents
in the Tohoku district, and 3) a summary of the char-
acteristics of asthma mortality in Japan．
THE RECENT CHANGE IN ASTHMA
DEATHS IN 5- TO 34-YEAR-OLDS IN JAPAN
Among the 5- to 34-year-old age group in Japan, more
than 300 persons died due to asthma yearly prior to
1996 ; however, the number declined dramatically in
both males and females beginning in 1997, reaching
116 in 2001 (Fig. 1). The asthma mortality rate per
100,000 in persons aged 5 to 34 years was less than
0.3 in 2001, the same level as in advanced countries in
Europe and North America.4
In the Tohoku district during 1992―2001, the great-
est number of asthma deaths in persons younger
than 40 years old was among persons 10 to 20 years
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Fig. 1 Annual number of asthma deaths in the 5- to 34-year-old age 
group in Japan over the period 1988―2001. 
N
um
be
r 
of
 a
st
hm
a 
de
at
hs
400
350
300
250
200
150
100
50
0
Total
Male
Female
Dominical year
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
Fig. 2 Ages of patients at the time of death due to an asthma atack in 
the Tohoku district. 
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old, and the next greatest number was among those
20 to 30 years old (Fig. 2). Increased risk of asthma
death in puberty and adolescence has been previ-
ously noted.6 In addition, it has been postulated that
reduced chemosensitivity to hypoxia and blunted per-
ception of dyspnea may predispose these patients to
fatal asthma attacks.7 Therefore, young people should
be educated more aggressively about asthma severity
and risk of death.
ASSOCIATION OF YEARLY DEATHS FROM
ASTHMA WITH SALES OF ANTI-ASTHMATIC
AGENTS IN THE TOHOKU DISTRICT :
1992―2001
The annual number of deaths from asthma attacks
and the corresponding sales of inhaled corticoster-
oids , anti-leukotrienes , and inhaled short-acting β-
agonists (SABA) in the Tohoku district during 1992―
2001 are shown in Figure 3. Annual data on the sales
of asthma medications were obtained from IMS Japan
KK. One of the most interesting trends was that ob-
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Fig. 3 Adjusted number of deaths due to asthma atacks over the period 1992―
2001 and sales of anti-asthma agents in the Tohoku district. 
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Fig. 4 Annual number of asthma deaths in persons of al ages, ≥60 years 
old, and ≥75 years old from 1988 to 2001 in Japan. 
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served with the anti-leukotriene, pranlukast. In 1995,
the number of deaths due to asthma attacks in the
Tohoku district was the highest and pranlukast , a
CysLT1 receptor antagonist, was first marketed in Ja-
pan at this time. The number of deaths decreased
substantially beginning in 1997, which coincided with
the increased use of pranlukast. In 2001, the sales of
anti-leukotrienes increased nearly sixfold and the
number of deaths decreased to almost one-fourth
compared with that in 1996. While the sales of in-
haled corticosteroids increased about threefold from
1992 to 1998 and about twofold from 1998 to 2001, the
number of deaths decreased almost one-half from
1992 to 1998 and another one-half from 1998 to 2001.
By contrast, the sales of inhaled SABA were almost
uniform for these 10 years. Thus, there were no rela-
tionships between the sales of inhaled SABA and the
decrease in the number of deaths in the Tohoku dis-
trict. The sales of other anti-asthmatic agents, such as
sustained-release theophylline, long-acting β-
agonists , and anti-allergy medications , were irrele-
vant to the decrease in the number of death due to
asthma attacks．
Because the population-based epidemiological
study based on an ecological design did not make any
direct connection between individual subjects who
used specific medications and the absence of fatal
asthma attacks , these results must be interpreted
with caution. However, the same protective effect of
inhaled corticosteroids on asthma mortality has been
reported in New Zealand,8 Israel,9 and Japan,10 and
their prophylactic effect was recently confirmed in a
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Fig. 5 Annual number of asthma deaths in persons of al ages and ≥75 
years old from 1990 to 2000 in the United States. Data were obtained from 
htp:/wonder.cdc.gov/mortSQL.html
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case-control study.11 On the other hand, our finding
that an increase in the sales of anti-leukotrienes was
related to a decrease in the number of deaths due to
asthma attacks supports Suissa’s finding10 that the
sharpest decrease in asthma mortality among 5- to 34-
year-olds followed the introduction of pranlukast. The
anti-inflammatory effect of inhaled corticosteroids
and the prophylactic effect of anti-leukotrienes on
asthma exacerbations 12 together appeared to de-
crease the number of deaths from asthma in the To-
hoku district.
Although the two epidemics in asthma mortality
have been reported to parallel the increase in the to-
tal sales of β-adrenergic agonists, we found no rela-
tionships between the sales of inhaled SABA and the
number of deaths due to asthma attacks in the To-
hoku district. One of the most practical and useful
ways by which a clinician can identify high-risk asth-
matic patients is to find those requesting repeat pre-
scriptions of two or more β-adrenergic receptor ago-
nist inhalers per month.13 Therefore, our finding sug-
gests that appropriate use of inhaled SABA does not
appear to be associated with deaths due to asthma at-
tacks.
CHARACTERISTICS IN ASTHMA MORTAL-
ITY OF JAPAN
Data on the number of asthma deaths in the total
population, in persons60 years old, and in those
75 years old from 1988 to 2001 in Japan (Fig. 4) show
that deaths in persons75 years old account for >50%
of all asthma deaths, particularly during the period
from 1997 to 2001, when it accounted for 61―66%. In
addition , deaths among those60 years old ac-
counted for >80% of all asthma deaths, particularly
from 1997 to 2001, when it accounted for 86―88%. In
France the presence of asthma has been reported to
increase the mortality rate in those >65 years old,14
and the recent increase of asthma deaths in the
United States has been reported to be due to the in-
crease in the population of women >65 years old.15
However, analysis of these numbers was undertaken
by obtaining data from the Internet on the number of
asthma deaths in the United States.16 In the United
States, as shown in Figure 5, the number of asthma
deaths among all ages was about 90―100% of the num-
ber in Japan in each calendar year, and the number of
deaths in those75 years old accounts for approxi-
mately one-third of all asthma deaths. Because the
U.S. population is about twice the Japanese popula-
tion, on the basis of this population ratio, the number
of asthma deaths in Japan was twice that in the
United States among all ages and four times that in
persons75 years old．
CONCLUSION
While the total number of deaths due to asthma in Ja-
pan has declined over the last decade, there is still a
higher mortality rate among Japan’s adolescents and
elderly. Given the prevalence of asthma mortality in
these two groups , improvements in the diagnosis ,
treatment, and management of asthma in general and
in particular, in the older population is crucial for or-
der to decreasing the total number of asthma deaths
in Japan. Specifically, we should take the following
steps : 1) establish more precise asthma diagnoses in
general , and especially in older persons, with particu-
lar care to exclude COPD17 and aspiration pneumo-
nia ; 2) use anti-inflammatory therapy more widely,
and particularly among older persons with asthma ;
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3 ) make an aerosol formulation of corticosteroids
available for older persons ; and 4) develop manage-
ment tools specifically for older patients that do not
require significant physical effort such as pulmonary
function tests．
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